Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
CANTO – Breast
- You are a woman aged 18 or older
- You have been diagnosed with invasive breast cancer confirmed by a tissue or cell sample
- There is no sign that the cancer has spread to other parts of your body at the time of joining
- You have not yet started any treatment for breast cancer (including surgery, even if it is already planned)
- You are covered by a social security or health insurance scheme in France
- You are able to read and communicate in French
- You agree to provide extra biological samples, complete questionnaires, and share information about your healthcare use
- (From February 2022 onwards) You also meet at least one of the following: you were under 45 years old when diagnosed; or your cancer falls into certain size/spread/type categories (confirm with trial site); or you are eligible for specific medications including Pembrolizumab, Olaparib, TDM1, Abemaciclib, or Ribociclib (confirm with trial site)
Who may not be able to join (CANTO – Breast):
- Your breast cancer has already spread to other parts of the body (metastatic)
- Your breast cancer has come back in the same area (local recurrence)
- You have had another cancer in the last 5 years, unless it was a common type of skin cancer or a very early-stage cervical condition
- You have already started treatment for your current breast cancer
- You have had a blood transfusion in the last six months
- You are currently under legal supervision, guardianship, or have restricted personal freedoms
Who might be able to join this trial:
CANTO – Lung
- You are aged 18 or older
- You have been diagnosed with lung cancer confirmed by a tissue or cell sample, or lung cancer is strongly suspected
- Your cancer has not spread to other parts of your body at the time of joining (if spread is found within 6 months of diagnosis, you would be removed from the study)
- You are eligible for treatment aimed at curing the cancer, specifically surgery or radiotherapy (patients receiving only chemotherapy, only standard radiotherapy, or only stereotactic radiotherapy would not be included — confirm with trial site)
- You have not yet received any treatment for your current lung cancer, including surgery
- You are covered by a social security or health protection scheme in France
- You are able to read and communicate in French
- You agree to provide extra biological samples, complete questionnaires, and share information about your healthcare use
Who may not be able to join (CANTO – Lung):
- Your lung cancer has already spread to other parts of the body (metastatic)
- Your lung cancer has come back in the same area (local relapse)
- You have had another cancer in the last 3 years, unless it was a common type of skin cancer or a very early-stage cervical condition
- You have already received treatment for your current lung cancer
- You have had a blood transfusion in the last six months
- You are currently under legal supervision, guardianship, or have restricted personal freedoms
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Inès VAZ-LUIS, Professor, Gustave Roussy - Villejuif
Phone: (0)6 71 48 27 76
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Evaluation of chronic toxicity in patients treated for non-metastatic breast cancer
Can't join this trial?
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.